EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Repurposing Disulfiram for Cancer Therapy: Mechanistic Insights and Translational Challenges

Anna Bilska-Wilkosz iD, Magdalena Górny iD, Małgorzata Iciek iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27177667 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Anna Bilska-Wilkosz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Chair of Medical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, Kopernika 7, 31-034 Kraków, Poland. Hauptthemen laut MEDLINE: Disulfiram, Drug Repositioning, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, National Science Centre, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disulfiram (DSF), long used as an aversive agent in alcohol dependence therapy, has recently regained attention as a promising candidate for oncological drug repurposing. After administration, DSF is rapidly reduced to diethyldithiocarbamate (DDC), which, in the presence of Cu2+, forms the complex Cu(DDC)2. This compound acts as a strong inducer of oxidative stress, an inhibitor of the ubiquitin–proteasome system, and a suppressor of endogenous hydrogen sulfide (H2S) synthesis. DSF also modifies protein and non-protein thiol groups, disrupting cancer cell metabolism and promoting apoptosis. Despite robust preclinical evidence, clinical translation remains limited. Key obstacles include DSF’s rapid metabolism, insufficient availability of free copper ions in humans, and the lack of predictive biomarkers capable of identifying responsive patients. Another challenge is DSF’s low oral bioavailability, which prevents the drug from reaching tumor tissue at therapeutically effective concentrations. Consequently, current research focuses on advanced nanocarrier systems designed to protect DSF from premature degradation and ensure its controlled release within the tumor microenvironment. This review summarizes the multifaceted anticancer mechanisms of DSF and discusses biological and pharmacological factors underlying the discrepancies between experimental findings and clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DisulfiramDrug RepositioningNeoplasmsAntineoplastic AgentsHumansAnimalsDitiocarbCopper

Stichwörter der Autor:innen

DDC/Cuanticancer therapybis(diethyldithiocarbamate)copper(II): Cu(DDC)2copper ions (Cu2+)diethyldithiocarbamate (DDC)disulfiramdrug repurposing

Substanzen

DisulfiramAntineoplastic AgentsDitiocarbCopper

Autor:innen und Institutionen

  • Chair of Medical Biochemistry, Faculty of Medicine, Jagiellonian University Medical College, Kopernika 7, 31-034 Kraków, Poland.

ORCID-Profile: Anna Bilska-Wilkosz, Magdalena Górny, Małgorzata Iciek

Förderung

  • National Science Centre
  • National Science Centre, Poland

Zitieren

APA

Bilska-Wilkosz, A., Górny, M., & Iciek, M. (2026). Repurposing Disulfiram for Cancer Therapy: Mechanistic Insights and Translational Challenges. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177667

Vancouver

Bilska-Wilkosz A, Górny M, Iciek M. Repurposing Disulfiram for Cancer Therapy: Mechanistic Insights and Translational Challenges. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177667

BibTeX
@article{BilskaWilkosz2026,
  author = {Bilska-Wilkosz, Anna and Górny, Magdalena and Iciek, Małgorzata},
  title = {Repurposing Disulfiram for Cancer Therapy: Mechanistic Insights and Translational Challenges},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27177667}
}
Kostenlos starten →